The National Institute of Allergy and Infectious Diseases, on Tuesday, stated that an independent board that reviews data from COVID-19 vaccine candidates has expressed concern over the vaccine efficacy data that AstraZeneca announced from its vaccine trial.

The NIAID said in a statement that the DSMB was concerned that AstraZeneca may have included outdated information from the trial, thus providing an incomplete view of the efficacy data. The NIAID asked AstraZeneca to work with the DSMB in order to review the data and make sure that the most accurate and updated efficacy data be made publicly available as early as possible.

In a statement released on Tuesday, AstraZeneca had stated that the numbers shared on Monday were based on a pre-specified interim evaluation that had a data cutoff of February 17… (CNN, March 23, 2021)